WO2005123137A3 - Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride - Google Patents

Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride Download PDF

Info

Publication number
WO2005123137A3
WO2005123137A3 PCT/IB2005/001716 IB2005001716W WO2005123137A3 WO 2005123137 A3 WO2005123137 A3 WO 2005123137A3 IB 2005001716 W IB2005001716 W IB 2005001716W WO 2005123137 A3 WO2005123137 A3 WO 2005123137A3
Authority
WO
WIPO (PCT)
Prior art keywords
pharmaceutical composition
lyophilized pharmaceutical
moxifloxacin hydrochloride
moxifloxacin
hydrochloride
Prior art date
Application number
PCT/IB2005/001716
Other languages
French (fr)
Other versions
WO2005123137A2 (en
Inventor
Ashish Sehgal
Jyoti Srivastava
Vinod Kumar Arora
Original Assignee
Ranbaxy Lab Ltd
Ashish Sehgal
Jyoti Srivastava
Vinod Kumar Arora
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ranbaxy Lab Ltd, Ashish Sehgal, Jyoti Srivastava, Vinod Kumar Arora filed Critical Ranbaxy Lab Ltd
Publication of WO2005123137A2 publication Critical patent/WO2005123137A2/en
Publication of WO2005123137A3 publication Critical patent/WO2005123137A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention relates to stable lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride as an active drug substance and the use of the preparation for preventing or treating bacterial infections in humans or animals.
PCT/IB2005/001716 2004-06-18 2005-06-17 Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride WO2005123137A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1150/DEL/2004 2004-06-18
IN1150DE2004 2004-06-18

Publications (2)

Publication Number Publication Date
WO2005123137A2 WO2005123137A2 (en) 2005-12-29
WO2005123137A3 true WO2005123137A3 (en) 2006-03-30

Family

ID=34977105

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2005/001716 WO2005123137A2 (en) 2004-06-18 2005-06-17 Lyophilized pharmaceutical composition comprising moxifloxacin hydrochloride

Country Status (1)

Country Link
WO (1) WO2005123137A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1106900A2 (en) * 2011-12-26 2013-11-05 Ems Sa SOLID PHARMACEUTICAL COMPOSITION UNDERSTANDING ANTIBOTH FAMILY OF QUINOLONES AND THE PROCESS OF OBTAINING THEM

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0219784A2 (en) * 1985-10-24 1987-04-29 Bayer Ag Infusion solutions of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-chinolon-3-carboxylic acid
WO2001010408A2 (en) * 1999-08-06 2001-02-15 Bayer Aktiengesellschaft Aqueous pharmaceutical composition containing moxifloxacin or salts thereof
WO2004039504A1 (en) * 2002-10-28 2004-05-13 Valois Sas Element for fixing a fluid product dispensing member and fluid product dispensing member comprising same

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0219784A2 (en) * 1985-10-24 1987-04-29 Bayer Ag Infusion solutions of 1-cyclopropyl-6-fluoro-1,4-dihydro-4-oxo-7-(1-piperazinyl)-chinolon-3-carboxylic acid
WO2001010408A2 (en) * 1999-08-06 2001-02-15 Bayer Aktiengesellschaft Aqueous pharmaceutical composition containing moxifloxacin or salts thereof
WO2004039504A1 (en) * 2002-10-28 2004-05-13 Valois Sas Element for fixing a fluid product dispensing member and fluid product dispensing member comprising same

Also Published As

Publication number Publication date
WO2005123137A2 (en) 2005-12-29

Similar Documents

Publication Publication Date Title
TW200621238A (en) Pharmaceutical formulation
MY143795A (en) Tetrahydropyridoindole derivatives
MY150958A (en) Compounds for the treatment of multi-drug resistant bacterial infections
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
WO2006089114A3 (en) Methods and compositions for treating an anthrax toxin mediated condition
ZA200705750B (en) Compositions and methods for stabilizing active pharmaceutical ingredients
WO2007070052A3 (en) Pharmaceutical compositions and methods for treating or preventing oxalate-related disease
EP1848541A4 (en) Method and device for ophthalmic administration of active pharmaceutical ingredients
WO2006108405A3 (en) Nanoparticle/active ingredient conjugate
EP1790637A4 (en) Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
IL180887A0 (en) Quinoline derivatives and insecticide comprising thereof as active ingredient
WO2006059234A3 (en) Bicyclic amides as kinase inhibitors
SI1765293T1 (en) Pharmaceutical compositions for drug delivery and methods of treating or preventing conditions using same
NO340679B1 (en) Pyridazine derivatives, pharmaceutical compositions comprising such and such compounds and preparations for use in therapeutically active substances for the treatment and prevention of diseases
ZA200807767B (en) Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient
WO2008087367A3 (en) Substituted (phenylthiazolyl)-phenyl-propan-1-one and (phenyloxazodyl)-phenyl-propan-1-one derivatives, preparations and uses of same
WO2009087474A3 (en) Agonists for antimicrobial peptide systems
IL189270A (en) Phosphonated rifamycins and derivatives thereof, pharmaceutical compositions comprising the same and uses thereof in the preparation of medicaments for the prevention and treatment of bone and joint infections
MXPA02001254A (en) Moxifloxacin formulation containing common salt.
GB0606805D0 (en) Organic compounds
WO2006021001A3 (en) Amphiphilic polynorbornene derivatives and methods of using the same
WO2008020229A3 (en) Antibacterial pyrrolecarboxamides
WO2008020227A3 (en) Antibacterial pyrrolecarboxamides
EP3915991A4 (en) Pyrrolopyrimidine derivative, and pharmaceutical composition for preventing or treating protein kinase-related disease comprising same as active ingredient
SI1954251T1 (en) Slow-release composition of fe salt as active ingredient, method for the preparation thereof and use of the same

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 7787/DELNP/2006

Country of ref document: IN

122 Ep: pct application non-entry in european phase